Conferences - Day 2
The Connect in Pharma conferences deliver high quality content designed in collaboration with world-leading organisations.
2022 morning session: pharma digitalization: challenges & threats
Morning session: POST-COVID: THE FUTURE FOR EUROPEAN PHARMA PRODUCTION
09:45 - 10:00
Introduction
Christian Wölbeling, Executive Industry Advisor & Senior Strategic Account Manager, Körber – ISPE
CHAIR
10:00 - 10:30
Threat landscape in the Pharmaceutical industry
We observed cyber threats in Europe and in the medical field. Through analyzing the field we were able to better understand the attackers, their motivations, and their techniques. Concluding the presentation with advice on how to better anticipate risks and respond to crises when they occur.
David Grout, CTO EMEA – Director Presales South Europe, Mandiant
10:35 - 11:05
Digitalization in production line – lesson learned
This presentation focused on solutions for the pharmaceutical industry to manage the plant digitalization: how to use different modules to measure OEE (Overall Equipment Effectiveness), to monitor production quality, to manage preventive maintenance, to make better and faster decisions based on facts from the production data.
Thierry Protas, Global Business Owner – Digital Factory, Antares Vision
CHAIR
11:20 - 11:50
Pharma 4.0 – The roadmap to digitalization
Pharma 4.0 is the end-to-end implementation of the industry 4.0 toolbox during the entire pharmaceutical lifecycle, from development to clinical trials, tech transfer, commercial manufacturing, and finally patient research.
We discussed the prerequisites that must be in place to implement a successful automation and regulatory compliance digital transformation.
Christian Wöbeling , Executive Industry Advisor & Senior Strategic Account Manager, Körber – ISPE
11:55 - 12:25
Novo Nordisk: What’s the meaning behind the word “digitalization” when referring to production lines?
visitors were guided along our digitalization journey through some MI (Manufacturing Intelligence) use cases on our production lines delivered by one of our data-driven & innovative-friendly employee and our local Digitalization A. Mger. A story of international collaboration, creative mindset, and challenges: which were marked by some top tips but also some flops! Both helping us to reach our company goals and drive change along the way.
Jérôme Vander Elst, Digitalization Associate Manager, Novo Nordisk
Reda Benhabyb, Data Scientist, Novo Nordisk
12:25 - 12:45
Q&A session
After the four morning sessions, visitors had the opportunity to get involved in a Q&A session.
Through getting involved in the Q&A session, it enabled curiosities to be quenched regarding the hot topics seen in the morning sessions.
Stay tuned regarding what will be expected at our upcoming 2023 show!
2022 afternoon session: how to scale up biotech products
Morning session: POST-COVID: THE FUTURE FOR EUROPEAN PHARMA PRODUCTION
14:15- 14:45
Ibex ® Design 2.0 Standard maBs DNA-to-IND program and subsequent manufacturing activities (Ibex ® Develop and Dedicate).
This presentation aimed to illustrate how Lonza brings any therapy to life by supporting its healthcare customers on the path to commercialization of recombinant proteins, especially monoclonal antibodies (mAbs).
Ibex® Design – DNA to IND in 11 months – is a new comprehensive service offering combining speed, guarantees and quality for standard mAbs. Innovative technologies and workflows further reduce the development time and improve the overall productivity. Parallel cell line and drug substance process development is one of the key elements to save time early, without increased development risks. The workflow relies on state-of-the-art process platforms, which ensure straightforward scale up to cGMP manufacturing. Ibex® Develop and Dedicate represent the next steps and aim at providing adaptative production capacities through the life of the product. Coupled with the strength of the Lonza global manufacturing network it will then ensure in the most rapid and cost-efficient way the clinical and commercial supply of the molecule. In addition, Ibex® Dedicate offers an agile, tailorable and technology agnostic response to unpredictable demand allowing you to delay investment decisions and decrease risk.
Pascal Torregrossa, Head of Manufacturing Operation, Lonza
CHAIR
14:50 - 15:20
Atinary SDLabs: ML software solutions and self-driving labs to accelerate R&D
In this conference, we described how Atinary’s SDLabs accelerates and improves R&D significantly by deploying machine learning (ML) and automation in the innovation process across industries, including pharma, biotech, energy and chemical. Lab scientists and operators can connect to SDLabs in the cloud and integrate with lab equipment and off-the-shelf robotic platforms to enable the Self-Driving Labs™. Thus, companies can deploy ML solutions seamlessly today, with no coding or ML expertise needed, starting with simulations or directly in the labs.
Loïc Roch, Co-founder & Chief Technology Officer, Atinary Technologies
CHAIR
15:35 - 16:05
Scaling your process – building value organically in your project
Testa Center is an open access testbed/user facility for education, innovation, and proof-of-concept experiments for production of biological products, e.g., monoclonal antibodies, proteins and viral vectors. Testa Center is a private-public partnership between the Swedish government and Cytiva to secure the growth of life science industry and its manufacturing capabilities. One main objective for Testa Center is to bridge the gap from discovery to industrialization. The purpose-built pilot-scale facility (non-GMP) is open for national and international academic research groups, small business enterprises and larger industry looking to verify their innovations in a production like environment. In Testa Center, researchers and young companies get accelerated by access to scientific expertise/know-how and a broad industrial network. Testa Center enables researchers to reduce or control risk, gain knowledge around their molecule and production process and, get access to production equipment in a flexible and dynamic environment.
Jesper Hedberg, CEO, Testa Center
CHAIR
16:05 - 16:35
Q&A session
After the four morning sessions, Visitors were given the opportunity to get involved in a Q&A session.
By getting involved in the Q&A session, curiosities were quenched regarding the hot topics seen in the afternoon sessions.